Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
losartan hydrochlorothiazide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Losartan/HCTZ |
| Name | Type | Description |
|---|---|---|
| losartan potassium (+) hydrochlorothiazide | DRUG | Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25. |
Inclusion Criteria: * Patient is male or female and = 18 years of age * Patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal Exclusion Criteria: * History of any condition, therapy, lab abnormality...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Losartan hydrochlorothiazide is a small molecule combination therapy used for the treatment of hypertension. It combines two active agents in a single product and is being developed by Merck & Company, Inc., which trades under the ticker MRK. The asset is in Phase 3 clinical development in the cardiovascular therapeutic area.
Losartan hydrochlorothiazide targets AGTR1, the angiotensin II receptor type 1. The target class is an antagonist, meaning the losartan component blocks AGTR1 signaling. The hydrochlorothiazide component is a thiazide diuretic. Together these two mechanisms lower blood pressure in patients with hypertension.
Losartan hydrochlorothiazide is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program for this fixed-dose hypertension combination.
Losartan hydrochlorothiazide is in Phase 3 clinical development. It is an investigational product and is not described as approved. The program includes one completed Phase 3 trial, and no trials are currently listed as active.
Losartan hydrochlorothiazide has been studied in the Phase 3 trial NCT00354991, titled Hyzaar Asia HEAALTH (0954A-950). That trial enrolled 437 participants with hypertension, included adults 18 years and older of all sexes, and has completed. It was an uncontrolled study without randomization or double blinding.